© 2022 Travere Therapeutics, Inc. All rights reserved. For US audiences. Chenodal®, Cholbam® and Total Care HUB® are registered trademarks of Travere Therapeutics, Inc. Thiola® and Thiola EC® are registered trademarks of Mission Pharmacal Company.
https://travere.com/wp-content/uploads/Retrophin-Solo-full-color.png 386 395 superadmin https://travere.com/wp-content/uploads/Travere-TxTM_Inline-fullcolor.png superadmin2020-10-09 11:44:212020-11-10 12:25:51Retrophin Announces Presentation of Abstracts at ASN Kidney Week 2020 Reimagined
SAN DIEGO, Oct. 09, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that it will present new data from a post-hoc analysis examining the proportion of patients with focal segmental glomerulosclerosis (FSGS) that achieved complete remission of proteinuria in the Phase 2 DUET Study, at the American Society of Nephrology (ASN) Kidney Week 2020 Reimagined. Read the press release >
https://travere.com/wp-content/uploads/Retrophin-Solo-full-color.png 386 395 superadmin https://travere.com/wp-content/uploads/Travere-TxTM_Inline-fullcolor.png superadmin2020-09-23 14:08:572020-09-30 14:38:20Retrophin Announces Enrollment of First 280 Patients in Pivotal Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
SAN DIEGO, Sept. 21, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the first 280 patients have been enrolled in the pivotal Phase 3 PROTECT Study evaluating the safety and efficacy of sparsentan in IgA nephropathy (IgAN). Read the press release >
https://travere.com/wp-content/uploads/Black-Womens-Health-Imperative-Logo.png 240 500 superadmin https://travere.com/wp-content/uploads/Travere-TxTM_Inline-fullcolor.png superadmin2020-09-22 09:56:592020-10-16 12:09:16Eric Dube, Ph.D., Speaks at Black Women’s Health Imperative Event
August 12, 2020 - the Black Women’s Health Imperative hosted a national webinar with its partner, the National Coalition of 100 Black Women, Inc. entitled “Our Health, Our Community: Mobilizing for the Survival of Black Women,” in partnership with EBONY.
https://travere.com/wp-content/uploads/PV100-300x228-1.png 228 300 superadmin https://travere.com/wp-content/uploads/Travere-TxTM_Inline-fullcolor.png superadmin2020-08-03 12:41:422020-09-29 12:27:54Retrophin President and Chief Executive Officer Eric Dube Named to the 2020 PharmaVOICE 100
SAN DIEGO (August 3, 2020) – Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., president and chief executive officer, has been named by PharmaVOICE magazine to the 2020 PharmaVOICE 100 – an award that recognizes the 100 Most Inspiring People in the life sciences industry. Read the press release >
https://travere.com/wp-content/uploads/Retrophin-Solo-full-color.png 386 395 superadmin https://travere.com/wp-content/uploads/Travere-TxTM_Inline-fullcolor.png superadmin2020-07-30 13:37:572020-11-10 12:28:50Retrophin Reports Second Quarter 2020 Financial Results
SAN DIEGO, July 30, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today reported its second quarter 2020 financial results and provided a corporate update. Read the press release >
https://travere.com/wp-content/uploads/Marshall-Summar.jpg 300 400 superadmin https://travere.com/wp-content/uploads/Travere-TxTM_Inline-fullcolor.png superadmin2020-07-16 15:16:312020-11-03 12:35:16Connecting More People to Optimal Rare Disease Care
An update on our partnership with Children's National Rare Disease Institute.
https://travere.com/wp-content/uploads/rare-revolution-logo-web.png 243 400 superadmin https://travere.com/wp-content/uploads/Travere-TxTM_Inline-fullcolor.png superadmin2020-07-01 09:42:532020-09-15 10:05:17Eric Dube, Ph.D., Interviewed by Rare Revolution
July 1, 2020 -- Our CEO and president Eric Dube, Ph.D., recently spoke with Rare Revolution Magazine about motivation, inspiration, challenges and hope.